737 related articles for article (PubMed ID: 17452404)
1. Combined effects of moderately elevated blood glucose and locally produced TGF-beta1 on glomerular morphology and renal collagen production.
Krag S; Nyengaard JR; Wogensen L
Nephrol Dial Transplant; 2007 Sep; 22(9):2485-96. PubMed ID: 17452404
[TBL] [Abstract][Full Text] [Related]
2. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury.
Yang K; Palm J; König J; Seeland U; Rosenkranz S; Feiden W; Rübe C; Rübe CE
Int J Radiat Biol; 2007 Oct; 83(10):665-76. PubMed ID: 17729161
[TBL] [Abstract][Full Text] [Related]
3. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
[TBL] [Abstract][Full Text] [Related]
4. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide.
Yuan P; Xue H; Zhou L; Qu L; Li C; Wang Z; Ni J; Yu C; Yao T; Huang Y; Wang R; Lu L
Nephrol Dial Transplant; 2011 Jul; 26(7):2119-26. PubMed ID: 21208996
[TBL] [Abstract][Full Text] [Related]
5. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
[TBL] [Abstract][Full Text] [Related]
6. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.
Seo JY; Park J; Yu MR; Kim YS; Ha H; Lee HB
Am J Nephrol; 2009; 30(6):481-90. PubMed ID: 19786738
[TBL] [Abstract][Full Text] [Related]
7. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease.
Krag S; Danielsen CC; Carmeliet P; Nyengaard J; Wogensen L
Kidney Int; 2005 Dec; 68(6):2651-66. PubMed ID: 16316341
[TBL] [Abstract][Full Text] [Related]
9. Isoliquiritigenin entails blockade of TGF-beta1-SMAD signaling for retarding high glucose-induced mesangial matrix accumulation.
Li J; Kang SW; Kim JL; Sung HY; Kwun IS; Kang YH
J Agric Food Chem; 2010 Mar; 58(5):3205-12. PubMed ID: 20146476
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
[TBL] [Abstract][Full Text] [Related]
11. Influence of C-peptide on early glomerular changes in diabetic mice.
Maezawa Y; Yokote K; Sonezaki K; Fujimoto M; Kobayashi K; Kawamura H; Tokuyama T; Takemoto M; Ueda S; Kuwaki T; Mori S; Wahren J; Saito Y
Diabetes Metab Res Rev; 2006; 22(4):313-22. PubMed ID: 16389646
[TBL] [Abstract][Full Text] [Related]
12. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis.
Ueberham E; Löw R; Ueberham U; Schönig K; Bujard H; Gebhardt R
Hepatology; 2003 May; 37(5):1067-78. PubMed ID: 12717387
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Yuan J; Jia R; Bao Y
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):118-26. PubMed ID: 17907099
[TBL] [Abstract][Full Text] [Related]
14. [Transforming growth factor-beta1 stimulates matrix metalloproteinase-9 production through ERK activation pathway and upregulation of Ets-1 protein].
Huang HC; Liu SY; Liang Y; Liu Y; Li JZ; Wang HY
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):328-31. PubMed ID: 15854510
[TBL] [Abstract][Full Text] [Related]
15. A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells.
Liu H; Peng Y; Liu F; Li J; Chen X; Liu Y; Zhang H
Cell Biol Int; 2007 May; 31(5):508-15. PubMed ID: 17196403
[TBL] [Abstract][Full Text] [Related]
16. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
17. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of gene expression in a rabbit model of intervertebral disc degeneration by real-time polymerase chain reaction.
Sobajima S; Shimer AL; Chadderdon RC; Kompel JF; Kim JS; Gilbertson LG; Kang JD
Spine J; 2005; 5(1):14-23. PubMed ID: 15653081
[TBL] [Abstract][Full Text] [Related]
19. [Influence of recombinant transforming growth factor-beta3 on collagen synthesis and deposition: experiment with rat cell model of liver fibrosis].
Li Q; Zhou X; Yu J; Qian W; Xu KS
Zhonghua Yi Xue Za Zhi; 2008 May; 88(18):1273-8. PubMed ID: 18844103
[TBL] [Abstract][Full Text] [Related]
20. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
